Strategies for Working with NGS Testing on Site in China

Did you know that NGS testing in China can be expedited with the right site relationships? 

As treatment options move towards enhanced personalization, NGS testing, or specific gene mutation testing, has become increasingly common as part of modern oncology and hematology clinical trials. When PSI Shanghai was contacted about a specific oncology trial requiring NGS testing, the team was able to contact 24 sites with relevant indication experience, and within 3 days, received interest from 15 of those sites to participate. 

In order to accelerate patient enrollment, PSI engages a trusted network of highly qualified sites to ensure that each trial’s needs are met with specific experience. Learn more about NGS testing in China with Lisa Lu, Country Manager.

If you have a phase 2/3 clinical trial requiring NGS testing, consider clinical trial sites in China. As experts at managing uncertainty, PSI CRO is consistently working to deliver studies on time and on budget. Discover more about our oncology and hematology experience here or contact us to speak with an expert today.

Transcript:

"Did you know the NGS testing status in China?

Modern oncology and hematology trials often require specific mutation testing, as we all move to more personalized medicine in time.

While this NGS technology is well established in China, it is not used in every study yet. We still have the capacity here. Let me share with you some recent cases.

We recently had a request for a specific oncology trial to be run in China. The protocol required sites to be able to run the NGS testing in the screening phase. PSI’s Shanghai team contacted 24 sites with study experience in this indication.

Overall, the site’s attitude was positive. We only had 3 days to check our sites. Among all of them, 15 sites expressed immediate interest and had the relevant NGS experience and equipment.

The results show that NGS testing is not a show-stopper for any modern trials which need this measured in China. Looking forward to seeing you in Shanghai."